Jade biosciences reports first quarter 2025 financial results and provides corporate update

Completed reverse merger and commenced trading on nasdaq as jbio closed financing, raising approximately $300 million to date, providing cash runway through 2027 lead candidate jade101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 san francisco and vancouver, british columbia, may 14, 2025 (globe newswire) -- jade biosciences, inc. (“jade”) (nasdaq: jbio), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending march 31, 2025, and provided a corporate update. “the start to 2025 marked a defining period for jade biosciences as we successfully completed our reverse merger, commenced trading as jbio on nasdaq, and closed a significant private financing led by a premier syndicate of healthcare investors,” said tom frohlich, chief executive officer of jade.
NDAQ Ratings Summary
NDAQ Quant Ranking